Drug Trial Radar · NCT02198794
Reducing Involuntary Movements in Participants With Tardive Dyskinesia
Last checked: Nov 20, 2026Latest source record: Apr 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
343
Actual
Start
Oct 20, 2014
Primary completion
Dec 6, 2019
Study completion Dec 14, 2020
Sponsor
- Lead sponsor
- Auspex Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of SD-809 in reducing the severity of abnormal involuntary movements of moderate to severe tardive dyskinesia. The purpose of part B is to establish the durability of effect of SD-809 following 1-week period of randomized withdrawal (SD-809 and placebo), followed by 12 weeks of maintenance with SD-809.
Conditions
- Tardive Dyskinesia
Interventions
SD-809Drug
SD-809 will be administered per dose and schedule specified in the arm.
PlaceboDrug
Placebo matching to SD-809 will be administered per schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A, B, and C: Number of Participants With Treatment-Emergent AEs (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to WithdrawalTime frame: Baseline up to the end of follow-up (4 weeks after the last dose of study drug; mean exposure: up to approximately 866.1 days)
- Part B: Change From Day 1 Visit in Total Motor AIMS Score at Day 7 Visit, as Assessed by Blinded Central Video RatingTime frame: Day 1 of Part B, Day 7 of Part B
Locations
82 sites in 6 countries. Site status is shown where the registry gives one.
Teva Investigational Site 145
Tuscaloosa, Alabama
Teva Investigational Site 107
Anaheim, California
Teva Investigational Site 108
Anaheim, California
Teva Investigational Site 123
Glendale, California
Teva Investigational Site 160
Irvine, California
Teva Investigational Site 176
Loma Linda, California
Teva Investigational Site 121
Los Angeles, California
Teva Investigational Site 147
Los Angeles, California
Teva Investigational Site 174
Norwalk, California
Teva Investigational Site 130
Oceanside, California
Teva Investigational Site 102
Orange, California
Teva Investigational Site 104
San Bernardino, California
Teva Investigational Site 110
San Diego, California
Teva Investigational Site 169
San Rafael, California
Teva Investigational Site 129
Englewood, Colorado
Teva Investigational Site 139
New Haven, Connecticut
Teva Investigational Site 156
Washington D.C., District of Columbia
Teva Investigational Site 157
Boca Raton, Florida
Teva Investigational Site 117
Gainesville, Florida
Teva Investigational Site 150
Lake City, Florida
Teva Investigational Site 153
Miami, Florida
Teva Investigational Site 162
Miami, Florida
Teva Investigational Site 112
Orlando, Florida
Teva Investigational Site 144
Port Charlotte, Florida
Teva Investigational Site 155
Augusta, Georgia
Teva Investigational Site 165
Decatur, Georgia
Teva Investigational Site 131
Chicago, Illinois
Teva Investigational Site 154
Baltimore, Maryland
Teva Investigational Site 101
Glen Burnie, Maryland
Teva Investigational Site 118
Creve Coeur, Missouri
Teva Investigational Site 142
Kansas City, Missouri
Teva Investigational Site 175
St Louis, Missouri
Teva Investigational Site 161
St Louis, Missouri
Teva Investigational Site 178
Lincoln, Nebraska
Teva Investigational Site 128
Albuquerque, New Mexico
Teva Investigational Site 146
Raleigh, North Carolina
Teva Investigational Site 114
Garfield Heights, Ohio
Teva Investigational Site 133
Charleston, South Carolina
Teva Investigational Site 149
Memphis, Tennessee
Teva Investigational Site 151
Fort Worth, Texas
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.